McDermott Will & Schulte advised EverZom on its €10 million financing round to develop innovative exosome-based therapies for the treatment of inflammatory and regenerative diseases.

The fundraising included, among others, the participation of Capital Grand Est, EIC Fund, Sorbonne Venture, Aloe Private Equity, Paris Business Angels and Capital Cell. The funds will notably enable EverZom to enter the clinical stage in 2026 with their first therapeutic candidate developed for Crohn’s perianal fistula, a condition affecting thousands of patients worldwide.

McDermott team that advised EverZom comprised Emmanuelle Trombe, Lucie Martin, Oriana Castelli and Alice Villagrasa.

Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.